Eli Lilly and Company (NYSE:LLY) Shares Purchased by Mainstream Capital Management LLC

Mainstream Capital Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 505.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,630 shares of the company's stock after acquiring an additional 1,361 shares during the quarter. Eli Lilly and Company comprises approximately 1.1% of Mainstream Capital Management LLC's portfolio, making the stock its 29th biggest holding. Mainstream Capital Management LLC's holdings in Eli Lilly and Company were worth $1,346,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of LLY. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and Company by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock valued at $57,320,226,000 after purchasing an additional 475,530 shares in the last quarter. Geode Capital Management LLC grew its position in Eli Lilly and Company by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock worth $13,389,651,000 after buying an additional 291,875 shares during the period. GAMMA Investing LLC increased its stake in Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after purchasing an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after buying an additional 2,012,129 shares in the last quarter. Finally, Norges Bank acquired a new position in Eli Lilly and Company during the fourth quarter worth about $8,407,908,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $0.32 during mid-day trading on Friday, reaching $779.60. The company's stock had a trading volume of 1,450,772 shares, compared to its average volume of 3,664,838. The firm has a market cap of $738.85 billion, a price-to-earnings ratio of 63.43, a PEG ratio of 1.14 and a beta of 0.40. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The business has a 50 day moving average price of $775.72 and a 200-day moving average price of $799.71. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 EPS. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.77%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. UBS Group reduced their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Guggenheim reaffirmed a "buy" rating and issued a $936.00 target price on shares of Eli Lilly and Company in a research report on Friday, June 20th. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average target price of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.